New immunotherapy plus chemo for untreated small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study is testing a new combination of two immunotherapy drugs (adebrelimab and vunakizumab) plus chemotherapy for people with previously untreated extensive-stage small cell lung cancer. The goal is to see if this approach helps shrink tumors and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have extensive-stage small cell lung cancer that has not been treated before.
- You are in good enough physical health to be up and about (ECOG score 0 or 1).
- You have at least one tumor that can be measured on a scan.
- Your blood counts, liver, kidney, and heart function are within healthy limits.
- You do not have an active autoimmune disease or a serious heart condition.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two experimental immunotherapy drugs (ivonescimab and cadonilimab) with standard chemotherapy for people with extensive-stage small cell lung cancer who have not had prior treatment. The goal is to see if this combination works better than chemo alone.
This study tests a new combination treatment for extensive-stage small cell lung cancer. You would receive an immunotherapy drug (adebrelimab) together with chemotherapy and a very low dose of chest radiation, to see if this helps control the cancer better.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and radiation therapy to see if it works better than standard treatment for people with extensive-stage small cell lung cancer who have not been treated before.
This trial tests a new immunotherapy drug (Adebelimab) combined with standard chemotherapy as a first treatment for extensive-stage small cell lung cancer. The goal is to see if this combination works better than chemo alone.
This trial is testing a new approach for extensive-stage small cell lung cancer (SCLC) that has not been treated before. It combines a high-dose chemotherapy regimen with a drug called adebrelimab (an immunotherapy) and a stem cell transplant to help your body recover. The goal is to see if this powerful combination can work better than standard treatment.
This trial tests a new combination of immunotherapy (adebrelimab), a targeted drug (famitinib), and standard chemotherapy for people with extensive stage small cell lung cancer who have not had treatment before. The goal is to see if this combination works better than chemotherapy alone.
Hear when a new Adebrelimab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.